NCT03332355 is a Phase 1 clinical trial of PAC-1 Compound in Glioblastoma Multiforme, sponsored by Vanquish Oncology, Inc..

Who is sponsoring NCT03332355?

NCT03332355 is sponsored by Vanquish Oncology, Inc..

What drugs are being tested in NCT03332355?

Interventions in NCT03332355: PAC-1 Compound.

What condition does NCT03332355 study?

NCT03332355 studies Glioblastoma Multiforme, Anaplastic Astrocytoma.

Is NCT03332355 still recruiting?

NCT03332355 is currently terminated. Last updated 24 May 2023.

Last reviewed 2023-05-24 · How we verify

NCT03332355

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

Terminated Phase 1 Last updated 24 May 2023

What this trial tests

Phase 1 trial testing PAC-1 Compound in Glioblastoma Multiforme in 18 participants. Terminated before completion.

Timeline

1 October 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Vanquish Oncology, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 October 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	3 locations across United States

Drugs / interventions tested

PAC-1 Compound — full drug profile →

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Anaplastic Astrocytoma — all drugs for Anaplastic Astrocytoma →

Sponsor

Vanquish Oncology, Inc. — full company profile →

Who can join

Adults 18 to 85, any sex, with Glioblastoma Multiforme or Anaplastic Astrocytoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objectives of this study are to determine the maximal tolerated dose (MTD) of PAC-1 in combination with temozolomide in patients with high grade glioma: glioblastoma multiforme (GBM) or anaplastic astrocytoma after progression following standard first line therapy (Component 2), by evaluation of toxicity and tolerability.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Lin A, Giuliano CJ, Palladino A, John KM, et al · · 2019 · cited 549× · PMID 31511426 · DOI 10.1126/scitranslmed.aaw8412
Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy.
Tarone L, Barutello G, Iussich S, Giacobino D, et al · · 2019 · cited 43× · PMID 31222484 · DOI 10.1007/s00262-019-02360-6
Targeting zinc metalloenzymes in coronavirus disease 2019.
Doboszewska U, Wlaź P, Nowak G, Młyniec K. · · 2020 · cited 25× · PMID 32671829 · DOI 10.1111/bph.15199
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Danciu OC, Holdhoff M, Peterson RA, Fischer JH, et al · · 2023 · cited 24× · PMID 36470974 · DOI 10.1038/s41416-022-02089-7
Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.
Peh J, Boudreau MW, Smith HM, Hergenrother PJ. · · 2018 · cited 20× · PMID 29909991 · DOI 10.1016/j.chembiol.2018.05.008
The evolution of small molecule enzyme activators.
Dow LF, Case AM, Paustian MP, Pinkerton BR, et al · · 2023 · cited 19× · PMID 37974956 · DOI 10.1039/d3md00399j
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Tonogai EJ, Huang S, Botham RC, Berry MR, et al · · 2021 · cited 8× · PMID 34216463 · DOI 10.1093/neuonc/noab161
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Crosley P, Farkkila A, Jenner AL, Burlot C, et al · · 2021 · cited 8× · PMID 33946730 · DOI 10.3390/ijms22094699

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03332355 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanquish Oncology, Inc.
Last refreshed: 24 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03332355.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing